ZOETIS INC COM USD0.01 CL 'A'
Symbol: ZTS
Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Charts
Company
Business Summary
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. It has a diversified business, commercializing products across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics and medicated feed additives. The Company operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
Financial Summary
BRIEF: For the three months ended 31 March 2024, Zoetis Inc revenues increased 10% to $2.19B. Net income increased 9% to $599M. Revenues reflect US segment increase of 16% to $1.16B, International segment increase of 3% to $1.01B, United States segment increase of 16% to $1.16B, Brazil segment increase of 20% to $101M. Net income was partially offset by Selling, General and Administrative Exp increase of 8% to $547M (expense).
Financials
Income Statement - All values are in U.S. Dollars
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Revenue | 8,544.00 | 8,080.00 | 7,776.00 | 6,675.00 | 6,260.00 | 5,825.00 |
Gross profit | 6,021.00 | 5,634.00 | 5,491.00 | 4,630.00 | 4,284.00 | 3,942.00 |
Operating Profit/Loss | 2,936.00 | 2,656.00 | 2,488.00 | 1,996.00 | 1,801.00 | 1,690.00 |
Profit Before Tax | 2,936.00 | 2,656.00 | 2,488.00 | 1,996.00 | 1,801.00 | 1,690.00 |
Profit After Tax | 2,340.00 | 2,111.00 | 2,034.00 | 1,636.00 | 1,500.00 | 1,379.00 |
Equity Holders of Parent Company | 2,344.00 | 2,114.00 | 2,037.00 | 1,638.00 | 1,500.00 | 1,428.00 |
Minority Interest | -2.00 | 1.00 | 4.00 | 6.00 | NIL | 4.00 |
Balance Sheet - All values are in U.S. Dollars
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Non-Current Assets | 7,943.00 | 7,419.00 | 6,970.00 | 6,998.00 | 6,797.00 | 6,378.00 |
Total Current Assets | 6,343.00 | 7,506.00 | 6,930.00 | 6,611.00 | 4,748.00 | 4,399.00 |
Total Assets | 14,286.00 | 14,925.00 | 13,900.00 | 13,609.00 | 11,545.00 | 10,777.00 |
Total Liabilities | 9,295.00 | 10,522.00 | 9,356.00 | 9,836.00 | 8,837.00 | 8,592.00 |
Total Net Assets | 4,991.00 | 4,403.00 | 4,544.00 | 3,773.00 | 2,708.00 | 2,185.00 |
Shareholders Funds | 4,997.00 | 4,405.00 | 4,543.00 | 3,769.00 | 2,708.00 | 2,185.00 |
Minority Interests | -2.00 | 1.00 | 4.00 | 6.00 | NIL | 4.00 |
Total Equity | 4,991.00 | 4,403.00 | 4,544.00 | 3,773.00 | 2,708.00 | 2,185.00 |
Outlook
Time & Sales
Sorry, sales information on this investment is not available at this time.